Welcome to our dedicated page for Defence Therapeu news (Ticker: DTCFF), a resource for investors and traders seeking the latest updates and insights on Defence Therapeu stock.
Defence Therapeutics Inc. (DTCFF) is a clinical-stage biopharmaceutical company pioneering next-generation cancer therapies and precision drug delivery systems. This page provides investors and industry stakeholders with timely updates on the company’s clinical trials, strategic partnerships, and technological advancements.
Access the latest press releases and news covering Accum™-enabled therapeutics, including radiopharmaceuticals, antibody-drug conjugates (ADCs), and immune-oncology vaccines. Stay informed about regulatory milestones, licensing agreements, and intellectual property developments that underscore the company’s position in the biotech sector.
Key updates include progress in Phase I trials for AccuTOX®, collaborations with research institutions, and patent grants for novel drug delivery methods. All content is curated to provide a comprehensive view of Defence Therapeutics’ scientific and corporate trajectory.
Bookmark this page for streamlined access to verified updates on DTCFF’s innovations in oncology and infectious disease treatment. Regularly updated to reflect the company’s evolving role in advancing targeted therapies.
Defence Therapeutics (DTCFF) has announced a collaboration with Canadian Nuclear Laboratories (CNL) to enhance cancer treatments using a combination of Actinium-225 (Ac-225) and Defence's proprietary Accum® technology. The partnership aims to improve the delivery and efficacy of radio-immunoconjugate therapies.
The collaboration will focus on preclinical studies where CNL will evaluate tumor-targeting antibodies modified with Accum® technology to transport Ac-225. The research will assess biodistribution, therapeutic potency, and safety profiles in rodent models. Accum® technology is designed to enhance the escape of Ac-225-antibody complexes from cellular endosomes, potentially improving their nuclear accumulation while reducing required dosage levels and side effects.
CNL will produce and supply Ac-225 from its Th-229/Ac-225 generator at Chalk River Laboratories. This initiative aligns with the growing radiopharmaceutical market, projected to reach USD 16.87 billion by 2033.
Defence Therapeutics (DTCFF) has appointed Dr. Elias Theodorou as Chief Operating Officer, effective April 2025. Dr. Theodorou brings over 25 years of experience in cancer research, stem cell differentiation, and gene delivery to the biopharmaceutical company.
A Yale University Ph.D. graduate and co-founder of Protos Biologics Inc., Dr. Theodorou previously served as Director of Research at WBC Biosciences , where he co-invented methods to enhance immune cells' anticancer properties. Based in the Boston area, he will focus on advancing Defence's Accum® technology and strengthening the company's position in the US biotech market.
As part of his compensation package, Dr. Theodorou has been granted 350,000 stock options, with 100,000 vesting immediately and 250,000 vesting in one year, exercisable at $1.07 per share over ten years.
Defence Therapeutics (OTCQB: DTCFF) has completed the second tranche of its non-brokered private placement, raising $3.915 million through a fully subscribed financing totaling $4.2 million. The company offered units at $0.60 per unit, with each unit comprising one common share and one warrant exercisable at $0.75 for 24 months.
The company paid $217,680 in finder's fees and issued 372,000 finder's warrants exercisable at $0.75 per share. PowerOne Capital Markets acted as a finder for part of the offering. Additionally, Defence granted 250,000 stock options to board members at $1.02 per share for ten years and 100,000 options to a consultant for three years.
The proceeds will be used to advance preclinical and clinical programs and for general working capital. All securities are subject to a four-month statutory hold period.
Defence Therapeutics (DTCFF) has announced its participation in the Biotech Showcase™ conference during the J.P. Morgan Healthcare Conference in San Francisco from January 13-16, 2025. The company's CEO and CSO will meet with industry leaders, potential partners, and investors to showcase their proprietary Accum® technology platform, particularly its applications in improving ADCs and developing targeted radiopharmaceutical therapies.
Additionally, Defence has completed the first tranche of its non-brokered private placement, raising $300,000 through units priced at $0.60 each. Each unit includes one common share and one warrant exercisable at $0.75 per share for 24 months. The company paid $24,000 in finder's fees and issued 40,000 finder's warrants. The proceeds will support preclinical and clinical programs and working capital.
Defence Therapeutics (DTCFF) has strengthened its patent portfolio with multiple key patent issuances and allowances. The USPTO issued a Notice of Allowance for US patent application 18/318,384, filed in May 2023, covering Accum®-based dimers and multimers. This patent, expected in early 2025, will provide market exclusivity until 2043 for Defence's AccuTOX® and ARM® anti-cancer programs.
The company also secured US patent 12,150,989 on November 26, 2024, extending protection of Accum®-based immunogenicity-enhancing variants to steroid acid-based compounds. Additionally, a Singaporean patent application was recently allowed and is expected to be granted in early 2025.
These developments strengthen Defence's intellectual property position for licensing and strategic partnerships, particularly in improving vaccine potency. The company plans additional national patent filings in Q3 2025 through PCT application PCT/CA2023/051758.
Defence Therapeutics (CSE: DTC) (OTCQB: DTCFF) has announced a non-brokered private placement to raise up to $4.2 million through the issuance of up to 7 million units at $0.60 per unit. Each unit consists of one common share and one warrant, with each warrant allowing the purchase of an additional common share at $0.75 for 24 months after closing.
The proceeds will be used to advance preclinical and clinical programs and for general working capital. The company may pay finder's fees, and securities will be subject to a four-month and one-day hold period following closing.
Defence Therapeutics (DTCFF) has announced Dr. Elias Theodorou has joined its board of directors. Dr. Theodorou brings over 25 years of experience in cancer research, stem cell differentiation, and gene delivery. He currently serves as Chief Scientific Officer at Protos Biologics Inc. and previously held leadership positions at WBC Biosciences, ATUM Inc., and Metagenomix Inc. The company granted him 100,000 incentive stock options, exercisable at $0.60 per share for three years.
Additionally, Mr. Arnab De has been appointed as CFO and Corporate Secretary, replacing Mr. Joseph Meagher and Miss Carrie Cesarone. The board now consists of five members: Sébastien Plouffe, Dr. Sarkis Meterissian, Dr. Philippe Lefrançois, Dr. Svetlana Selivanova, and Dr. Elias Theodorou.
Defence Therapeutics announces its annual general and special meeting of shareholders scheduled for December 12th, 2024, at 10:00 a.m. (Pacific Time) in Vancouver. Shareholders of record as of November 4, 2024, are eligible to vote, with a proxy deadline of December 10th, 2024, at 10:00 a.m. Due to a Canada Post labour strike, shareholders may experience delays in receiving the Information Circular dated November 8, 2024. The company encourages shareholders to access materials electronically via SEDAR+ and vote according to the Circular's instructions.
Defence Therapeutics announces plans to license its proprietary Accum® technology to pharmaceutical companies developing Antibody Drug Conjugates (ADCs). The technology enhances the delivery and efficacy of biologics by overcoming endosomal entrapment, potentially increasing therapeutic potency and reducing dosing requirements. The company aims to generate revenue through licensing while establishing its technology as an industry standard. Additionally, Defence completed a private placement, issuing 50,000 units at $0.50 per unit for proceeds of $25,000, and amended terms for 1,497,780 warrants, reducing their exercise price from $1.75 to $0.75.
Defence Therapeutics has appointed Dr. Maxime Parisotto as Chief Scientific Officer, Director of Science and Business Development. Dr. Parisotto brings over 20 years of experience in biochemistry, drug development, and innovation, holding a PhD focused on breast cancer and metabolism. His background includes postdoctoral fellowships at IGBMC and Université de Montréal, and a senior analyst role at adMare Bioinnovations. He will complete his MBA from Sherbrooke University in April 2025. The company has granted him 100,000 incentive stock options, exercisable at 60 cents per share for three years. The announcement also notes that Dr. Moutih Rafei has left the company.
